IL7 and lung carcinoma: In a murine lung cancer model, IL‐7 + sCD127 treatment enhanced antigen presentation, T‐cell activity and inflammation in the tumor microenvironment which reduced tumor burden and improved survival compared with IL‐7 alone.18